Evidence map›Paper›PMID 41809723›Full record

ArticleCase reports in oncological medicine2026

First-Line Treatment of Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor: A Case Report and Review of the Literature.

Qingyang Wen, Mengle Long, Feng Li, Yaya Peng, Jiarong Yi, Yongjun Wu, Di Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncological medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qingyang WenDepartment of Oncology, Graduate Collaborative Training Base of The First People's Hospital of Xiangtan City, Hengyang Medical School, University of South China, Hengyang, Hunan, China, usc.edu.cn.
Mengle LongDepartment of Oncology, Graduate Collaborative Training Base of The First People's Hospital of Xiangtan City, Hengyang Medical School, University of South China, Hengyang, Hunan, China, usc.edu.cn.
Feng LiDepartment of Medical Oncology, The First People's Hospital of Xiangtan City, Xiangtan, Hunan, China.
Yaya PengDepartment of Pathology, The First People's Hospital of Xiangtan City, Xiangtan, Hunan Province, China.
Jiarong YiDepartment of Medical Oncology, The First People's Hospital of Xiangtan City, Xiangtan, Hunan, China.
Yongjun WuDepartment of Pathology, Xiangtan Center Hospital, Xiangtan City, Hunan province, China.ORCID https://orcid.org/0009-0001-8009-5526
Di WangDepartment of Medical Oncology, The First People's Hospital of Xiangtan City, Xiangtan, Hunan, China.ORCID https://orcid.org/0000-0002-0551-2713

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Thoracic SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) of the chest is a highly aggressive smoking-related thoracic malignancy with a median overall survival (OS) of only 4-7 months. Case Presentation: In this article, we report a case of a 74-year-old male patient who was admitted to the hospital with recurrent cough with sputum and CT suggestive of a right pleural occupying lesion. Admission to the hospital and perfect CT showed right pleural thickening with multiple metastases in the mediastinum and liver, and the diagnosis of SMARCA4-UT (SMARCA4 expression deletion) was confirmed by pathologic biopsy and immunohistochemistry. The genetic test map suggested high PD-L1 expression (TPS 80%) and the patient was treated with sindilizumab (200 mg q3w) combined with bevacizumab (500 mg q3w). Grade 3 immune myocarditis occurred during treatment, and bevacizumab maintenance therapy was continued after discontinuing immunosuppression. During follow-up, the patient achieved a final OS of 18 months. Conclusions: This case suggests that PD-1 inhibitors combined with antiangiogenic therapy may improve the prognosis of SMARCA4-UT, but the adverse effects observed during the treatment course demanded equally critical attention.

Indexed as

antivascular therapycase reportimmune-mediated myocarditisimmunohistochemistrythoracic SMARCA4-deficient undifferentiated tumor

Identifiers

PMID41809723
PMCPMC12969486

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.